TEVA 57.99 Teva Pharmaceutical Industries Ltd $TEV
Post# of 116
Posted On: 11/05/2014 8:52:33 AM
TEVA 57.99 Teva Pharmaceutical Industries Ltd $TEVA Hit a 52 week high of 58.25 Closing the day 11/04/14 at 57.99 +0.19 +0.33% With a day low of 57.03 and a total volume of 5,788,500.
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Key Takeaways From Teva Pharmaceutical Industries Ltd.'s Third-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Tue Nov 04, 5:35PM CST
Pharma companies far and wide are going through a difficult period because of the patent cliff. On the flip side, specialty and generic drugmakers have largely been the beneficiaries of top-selling drugs losing exclusivity, driving nice upticks in...
TEVA: 57.99 (+0.19)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 195.12 (+1.98), ABBV: 62.66 (-0.59), TEVA: 57.99 (+0.19), BMY: 57.84 (+0.04)
Quarterly Earnings Releases, Strategic Partnerships, and Scheduled Financial Results - Research Reports on Banco Bradesco, Blackstone, Teva, Apache and Noble
PR Newswire - Tue Nov 04, 7:45AM CST
Today, Analysts Review released its research reports regarding Banco Bradesco S.A. (NYSE: BBD), The Blackstone Group L.P. (NYSE: BX), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Apache Corp. (NYSE: APA) and Noble Corp. Plc (NYSE: NE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7667-100free.
BX: 30.34 (+0.04), BBD: 14.73 (+0.03), APA: 74.21 (-2.19), TEVA: 57.99 (+0.19), NE: 19.15 (-1.16)
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Business Wire - Tue Nov 04, 7:02AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS). Additionally, Teva has screened the first patient in the LEGATO-HD trial, which will evaluate laquinimod in Huntington's disease. Currently, there are no approved therapies available for the treatment of PPMS or the treatment of Huntington's disease, beyond symptom management.
TEVA: 57.99 (+0.19)
Upgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Mon Nov 03, 8:00AM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) was upgraded from Sector Perform to Outperform at RBC Capital today. The stock closed yesterday at $56.47 on volume of 7.8 million shares, above average daily volume of 4.1 million. Teva Pharmaceutical Industries has overhead space with shares priced $56.47, or 7.4% below the average consensus analyst price target of $60.96. The stock should find initial support at its 50-day moving average (MA) of $52.68 and further support at its 200-day MA of $50.96.
TEVA: 57.99 (+0.19)
BioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen(R) for the Treatment of the Dry Form of Age-Related Macular Degeneration
Business Wire - Mon Nov 03, 6:00AM CST
--No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries
BTX: 3.43 (+0.01), TEVA: 57.99 (+0.19)
Teva Beats Q3 Earnings Expectations, Updates Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:10PM CDT
Teva (TEVA) has seven U.S. launches and multiple international launches lined up for the fourth quarter.
IPXL: 29.34 (+0.30), ACT: 245.32 (-2.18), MYL: 53.75 (+0.16), TEVA: 57.99 (+0.19)
Teva Pharmaceutical (TEVA) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 11:10AM CDT
The following Teva Pharmaceutical (TEVA) conference call took place on October 30, 2014, 08:00 AM ET. This is a transcript of that earnings call:
TEVA: 57.99 (+0.19)
Is Mylan's Lively Third Quarter the Start of Something Special?
Dan Carroll, The Motley Fool - Motley Fool - Thu Oct 30, 8:51PM CDT
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more...
MYL: 53.75 (+0.16), TEVA: 57.99 (+0.19)
Teva ups full-year EPS outlook
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Multiple sclerosis drug Copaxone boosted Teva Pharmaceutical Industries' (TEVA) Q3, as earnings rose 3.9% to $1.32, topping views for $1.24. But revenue dipped 0.02% to $5.06 bil, missing views for $5.1 bil. The company narrowed its full-year EPS...
TEVA: 57.99 (+0.19)
Watch for Teva Pharmaceutical Industries to Potentially Pullback After Gaining 3.63% Yesterday
Comtex SmarTrend(R) - Thu Oct 30, 3:42PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.99 (+0.19)
SmarTrend Watching for Potential Pullback in Shares of Teva Pharmaceutical Industries After 3.63% Gain
Comtex SmarTrend(R) - Thu Oct 30, 3:41PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.99 (+0.19)
Dow Surges 221 Points on GDP Data, Visa Earnings After Fed’s QE End
at The Street - Thu Oct 30, 3:18PM CDT
U.S. stock markets closed far higher on Thursday as the Commerce Department said U.S. gross domestic product rose 3.5% in the third quarter.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.26 (-0.07), TEVA: 57.99 (+0.19)
Stock Market Today: Visa, MasterCard Push Markets Up as Investors Digest 3.5% GDP Growth
at The Street - Thu Oct 30, 2:28PM CDT
While it brought the year’s biggest surge in volatility, October may represent a turning point for U.S. markets.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
Stock Market Today: Stocks Move Higher on Visa Earnings, 3.5% GDP Growth
at The Street - Thu Oct 30, 10:59AM CDT
U.S. stocks trade mixed after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
Stock Market Today: Futures Fall as U.S. Economy Grows 3.5% and Fed Ends QE
at The Street - Thu Oct 30, 8:07AM CDT
U.S. stock futures are trading lower after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
Teva Reports Third Quarter 2014 Results
Business Wire - Thu Oct 30, 6:04AM CDT
--Non-GAAP operating income of $1.5 billion, an increase of 13% from the third quarter of 2013. GAAP operating income of $1.1 billion, up 39%.
TEVA: 57.99 (+0.19)
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Key Takeaways From Teva Pharmaceutical Industries Ltd.'s Third-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Tue Nov 04, 5:35PM CST
Pharma companies far and wide are going through a difficult period because of the patent cliff. On the flip side, specialty and generic drugmakers have largely been the beneficiaries of top-selling drugs losing exclusivity, driving nice upticks in...
TEVA: 57.99 (+0.19)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 195.12 (+1.98), ABBV: 62.66 (-0.59), TEVA: 57.99 (+0.19), BMY: 57.84 (+0.04)
Quarterly Earnings Releases, Strategic Partnerships, and Scheduled Financial Results - Research Reports on Banco Bradesco, Blackstone, Teva, Apache and Noble
PR Newswire - Tue Nov 04, 7:45AM CST
Today, Analysts Review released its research reports regarding Banco Bradesco S.A. (NYSE: BBD), The Blackstone Group L.P. (NYSE: BX), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Apache Corp. (NYSE: APA) and Noble Corp. Plc (NYSE: NE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7667-100free.
BX: 30.34 (+0.04), BBD: 14.73 (+0.03), APA: 74.21 (-2.19), TEVA: 57.99 (+0.19), NE: 19.15 (-1.16)
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Business Wire - Tue Nov 04, 7:02AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS). Additionally, Teva has screened the first patient in the LEGATO-HD trial, which will evaluate laquinimod in Huntington's disease. Currently, there are no approved therapies available for the treatment of PPMS or the treatment of Huntington's disease, beyond symptom management.
TEVA: 57.99 (+0.19)
Upgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Mon Nov 03, 8:00AM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) was upgraded from Sector Perform to Outperform at RBC Capital today. The stock closed yesterday at $56.47 on volume of 7.8 million shares, above average daily volume of 4.1 million. Teva Pharmaceutical Industries has overhead space with shares priced $56.47, or 7.4% below the average consensus analyst price target of $60.96. The stock should find initial support at its 50-day moving average (MA) of $52.68 and further support at its 200-day MA of $50.96.
TEVA: 57.99 (+0.19)
BioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen(R) for the Treatment of the Dry Form of Age-Related Macular Degeneration
Business Wire - Mon Nov 03, 6:00AM CST
--No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries
BTX: 3.43 (+0.01), TEVA: 57.99 (+0.19)
Teva Beats Q3 Earnings Expectations, Updates Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:10PM CDT
Teva (TEVA) has seven U.S. launches and multiple international launches lined up for the fourth quarter.
IPXL: 29.34 (+0.30), ACT: 245.32 (-2.18), MYL: 53.75 (+0.16), TEVA: 57.99 (+0.19)
Teva Pharmaceutical (TEVA) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 11:10AM CDT
The following Teva Pharmaceutical (TEVA) conference call took place on October 30, 2014, 08:00 AM ET. This is a transcript of that earnings call:
TEVA: 57.99 (+0.19)
Is Mylan's Lively Third Quarter the Start of Something Special?
Dan Carroll, The Motley Fool - Motley Fool - Thu Oct 30, 8:51PM CDT
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more...
MYL: 53.75 (+0.16), TEVA: 57.99 (+0.19)
Teva ups full-year EPS outlook
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Multiple sclerosis drug Copaxone boosted Teva Pharmaceutical Industries' (TEVA) Q3, as earnings rose 3.9% to $1.32, topping views for $1.24. But revenue dipped 0.02% to $5.06 bil, missing views for $5.1 bil. The company narrowed its full-year EPS...
TEVA: 57.99 (+0.19)
Watch for Teva Pharmaceutical Industries to Potentially Pullback After Gaining 3.63% Yesterday
Comtex SmarTrend(R) - Thu Oct 30, 3:42PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.99 (+0.19)
SmarTrend Watching for Potential Pullback in Shares of Teva Pharmaceutical Industries After 3.63% Gain
Comtex SmarTrend(R) - Thu Oct 30, 3:41PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.99 (+0.19)
Dow Surges 221 Points on GDP Data, Visa Earnings After Fed’s QE End
at The Street - Thu Oct 30, 3:18PM CDT
U.S. stock markets closed far higher on Thursday as the Commerce Department said U.S. gross domestic product rose 3.5% in the third quarter.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.26 (-0.07), TEVA: 57.99 (+0.19)
Stock Market Today: Visa, MasterCard Push Markets Up as Investors Digest 3.5% GDP Growth
at The Street - Thu Oct 30, 2:28PM CDT
While it brought the year’s biggest surge in volatility, October may represent a turning point for U.S. markets.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
Stock Market Today: Stocks Move Higher on Visa Earnings, 3.5% GDP Growth
at The Street - Thu Oct 30, 10:59AM CDT
U.S. stocks trade mixed after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
Stock Market Today: Futures Fall as U.S. Economy Grows 3.5% and Fed Ends QE
at The Street - Thu Oct 30, 8:07AM CDT
U.S. stock futures are trading lower after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 82.27 (-2.05), COP: 68.77 (-1.79), DWA: 21.92 (-0.12), SBUX: 76.71 (+0.61), RDS.A: 68.79 (-1.24), V: 242.97 (+1.43), LNKD: 238.43 (+5.35), TEVA: 57.99 (+0.19), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
Teva Reports Third Quarter 2014 Results
Business Wire - Thu Oct 30, 6:04AM CDT
--Non-GAAP operating income of $1.5 billion, an increase of 13% from the third quarter of 2013. GAAP operating income of $1.1 billion, up 39%.
TEVA: 57.99 (+0.19)
(0)
(0)Teva Pharmaceutical Industries Limited (TEVA) Stock Research Links
Scroll down for more posts ▼